Lowe's, Target Miss...
Services: Diversified Services
Genetic Technologies Limited (GENE: NASDAQ)
$3.02 -0.08 | -2.55%
05/22/13 - 12:34 PM ET
Company Income Statement
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Sales | 11.60M | 19.53M | 8.29M | 9.20M |
| Cost of Sales | 1.42M | 1.52M | 2.31M | 1.78M |
| Gross Operating Profit | 10.18M | 18.02M | 5.98M | 7.42M |
| Selling, General, and Administrative Expenses | 11.53M | 11.56M | 9.60M | 9.32M |
| Research & Development | 4.13M | 4.68M | 76.49K | 603.88K |
| Operating Income before D & A (EBITDA) | -5.47M | 1.78M | -3.69M | -2.51M |
| Depreciation & Amortization | 575.48K | 659.29K | 3.15M | 3.22M |
| Interest Income | 624.50K | 0.00 | 0.00 | 0.00 |
| Other Income - Net | 46.75K | -68.62K | 496.46K | -284.52K |
| Special Income / Charges | 0.00 | 0.00 | -1.52M | -256.66K |
| Total Income Before Interest Expenses (EBIT) | -5.38M | 1.05M | -7.87M | -6.27M |
| Interest Expense | 46.31K | 87.57K | 85.34K | 72.23K |
| Pre-Tax Income | -5.42M | 963.32K | -7.95M | -6.34M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | -9.53K | -9.26K | -9.72K | -13.92K |
| Net Income From Continuing Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -5.41M | 972.58K | -7.94M | -6.33M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0.00 | 0.00 | 1.52M | 256.66K |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -0.35 | 0.07 | -0.64 | -0.51 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.35 | 0.07 | -0.64 | -0.51 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.35 | 0.07 | -0.64 | -0.51 |
| Basic Normalized Net Income/Share | n.a. | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -0.35 | 0.07 | -0.64 | -0.51 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.35 | 0.07 | -0.64 | -0.51 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.35 | 0.07 | -0.64 | -0.51 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
n.a. | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with GENE
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor14 Penny Stocks Get Delisti...
- UserExperimental Equities
- UserMBW
- Userann's prorfolio
Latest GENE Headlines from TheStreet
- STUDY VALIDATES BREVAGen MORE ACCURATELY IDENTIFIES BREAST CANCER RISK LEADING TO INCREASED BREAST HEALTH COMPLIANCE 04.15.13 | 12:04 pm
- The Centers For Women's Health In Stamford CT Pioneers Breast Cancer Risk Assessment 03.18.13 | 12:03 pm
- 5 Stocks Ready to Break Out 02.22.13 | 12:02 pm
- 4 Stocks Under $10 Making Big Moves 10.19.12 | 02:10 pm
- 4 Biotech Stocks Under $10 Soaring Higher 09.25.12 | 02:09 pm
- 8 Stocks Under $10 Ripping Higher 01.26.12 | 02:01 pm
- Optimer Soars on Antibiotic Data 11.11.08 | 12:11 pm
- Biotech Buzz: Big Strides in Alzheimer's Drugs
01.10.08 | 05:01 pm - Funny Money 12.10.07 | 01:12 pm
- Ties May Bind Apple's CEO to Board 09.06.06 | 04:09 pm
Press Releases for GENE
- BREVAGen Reclassified 64% Of Intermediate Gail Risk Subjects(1) (Graphic: Business Wire) - Business Wire 04.10.12 | 09:04 am
- Break-Through Invention For Treating Cancer - Business Wire 11.07.11 | 10:11 am
- Genetic Technologies Limited Announces Quarterly Activities Report For The Quarter Ended 30 September 2011 - Business Wire 10.26.11 | 11:10 am
- Genetic Technologies’ BREVAGen™ Changing The Way US Physicians Assess Breast Cancer Risk - Business Wire 10.18.11 | 09:10 am
- Genetic Technologies Limited Appoints Dr. Mervyn Cass As Company Director - Business Wire 10.03.11 | 10:10 am
Partner Headlines for GENE
- Morning Market Losers - Benzinga 11.28.12 | 09:11 am
- Genetic Technologies Executes Covenant Not to Sue And Release Agreement with One Lambda - Benzinga 10.18.12 | 01:10 pm
- 3 Best Biotech Stocks For This Week (Part VI) - Seeking Alpha 10.16.12 | 08:10 am
- Morning Market Movers - Benzinga 09.25.12 | 09:09 am
- Genetic Technologies Moving On News This Morning - Seeking Alpha 08.08.12 | 09:08 am
- Healthcare Business Recap: Merck's Potential AIDS CURE, Genetic Tech SPIKES - Wall St. Cheat Sheet 07.27.12 | 08:07 am
- Genetic Technologies Executes Exclusive Distribution Agreement with Rosetta Genomics - Benzinga 06.01.12 | 01:06 pm
- Netflix, Take-Two Among Stocks Attracting Investors and Traders Now - Wall St. Cheat Sheet 05.23.12 | 02:05 am
- Afternoon Market Top Percentage Gainers and Losers (CAAS, GENE, HNSN, SYMX, TPX, SCOK, QXM, IDIX, AIB, HERO) - Benzinga 04.08.11 | 01:04 pm
